Skip to main content

NHGRI Offering $12.5M for GWAS of Treatment Response and Coordinating Center

NEW YORK (GenomeWeb News) – The National Human Genome Research Institute plans to spend $8.8 million to fund three to five genome-wide association studies of treatment response in randomized clinical trials over the next three years, and will use another $3.7 million for a coordinating center to support those programs.
The National Institutes of Health in two requests for applications this week said it wants the NHGRI to use the coordinating center, and community resources such as the Database of Genotype and Phenotype at the National Center for Biotechnology Information, to support “rapid and widespread sharing” of the genotype data that these studies generate. For the purposes of this program, “rapid” means that data and samples must be ready for submission within nine months of the award, and for unmasked analysis within 12 months of the award.
NIH stipulates that applicants should not include the costs for genome-wide genotyping in their applications, as these will be supported separately by NHGRI.
NHGRI is encouraging population-based studies, and does not require applicants to propose hospital or clinic-based research programs. For this research program, NHGRI is defining a treatment as “an intervention, whether involving drug, dietary, and/or lifestyle modification, that aims to reduce morbidity and/or prevent disease.”
NHGRI has set three goals for the program. Researchers should seek to identify genetic variants that influence individual treatment response; determine whether specific treatments are more or less effective in groups that are defined by genotype; and develop and disseminate methods for adding genome-wide technologies to randomized clinical trials and interpreting the results in a randomized treatment context.
For this grant program, the budget period covers three years, and direct costs are limited to $375,000 in fiscal 2009, $600,000 in fiscal 2010, and $610,000 in fiscal 2011.
Over the same respective period, the Coordinating Center program will provide one grantee with direct costs of around $1.2 million per year.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.